Healthcare

For the year ended 30 June 2026, PolyNovo Limited (ASX:PNV) reported total revenue of AUD 150.0 million, an increase of 16.1%. Commercial sales were AUD 138.4 million, up 16.7%. The commercial sales measure reflects the company’s product business, while total revenue includes other income …

Orthocell Limited (ASX:OCC) develops, manufactures and supplies regenerative medicine products for repairing nerve and other musculoskeletal tissue. Its collagen-based Remplir nerve repair device and Striate+ dental regeneration product form part of its commercial portfolio. During FY26, growth in product revenue coincided with an expanded …

Optiscan Imaging Limited (ASX:OIL) develops miniature confocal imaging technology used to obtain real-time, high-resolution images of living tissue for diagnostic, surgical and research applications. Its 2026 announcements have centred on US regulatory submissions for imaging devices, clinical research programmes and the translation of digital …

OmniCAR is a modular cell therapy approach. Conventional chimeric antigen receptor T-cell (CAR-T) treatments use engineered immune cells designed to recognise particular markers on cancer cells. Prescient Therapeutics Limited (ASX:PTX) is exploring an architecture in which the cellular component and the tumour-targeting binder are …

PYC Therapeutics Limited (ASX:PYC) develops RNA-based medicines for genetic diseases, using technology designed to carry therapeutic oligonucleotides into cells. Its development work spans inherited eye disorders and kidney disease. During 2026, the company continued clinical evaluation of multiple programs, making drug delivery, patient safety …

RC220 is being investigated across several oncology settings rather than as an approved treatment for those indications. Racura Oncology Limited (ASX:RAC) describes bisantrene as a small-molecule anticancer agent whose activity includes interactions with G4-DNA and RNA and inhibition of the cancer-related regulator MYC. These …

Recce Pharmaceuticals Limited (ASX:RCE) develops synthetic anti-infective treatments intended for serious bacterial infections, including infections involving antibiotic-resistant organisms. Its lead compound, RECCE 327 (R327), is being developed in multiple formulations. During 2026, the company’s clinical focus has included its topical gel formulation, R327G, for …